Clinical Trial Update: SERS Sensor Based on CHA Reaction for EGFR Mutation Typing in Advanced Lung Cancer

View source ↗

Summary

The trial evaluates a SERS-based sensor leveraging a CHA reaction to type EGFR mutations in advanced lung cancer. The study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Snippet

Sponsor: Fuzhou General Hospital | Conditions: Lung Cancer in Normal and Malignant Tumors | Status: NOT_YET_RECRUITING